Backed by AI technology, Aigen Sciences Inc. raised ₩12 billion (US$8.8 million) in a series A financing round to further advance its cancer and rare disease drug pipelines. Aigen said Oct. 16 that the series A round was joined by existing investors Partners Investment, Quad Investment Management and Medytox Venture Investment, as well new investors Premier Partners, K2 Investment Partners and Scale Up Partners.
Jiangsu Alicorn Pharmaceutical Co. Ltd. has described AP2-associated protein kinase 1 (AAK1) inhibitors reported to be useful for the treatment of Alzheimer’s disease, bipolar disorder, Parkinson’s disease, schizophrenia, diabetic peripheral neuropathy and postherpetic neuralgia.
Shanghai Yidi Biotechnology Co. Ltd. has identified dihydrothienopyrimidine compounds acting as phosphodiesterase PDE4B2 and/or phosphodiesterase PDE4D2 inhibitors reported to be useful for the treatment of autoimmune disorders, metabolic diseases, neurological diseases and inflammatory disorders.
Immunophage Biomedical Co. Ltd. has divulged G-protein coupled receptor 183 (GPR183; EBI2) antagonists reported to be useful for the treatment of autoimmune disease, cancer, liver diseases, osteoporosis and neuropathic pain.
Shanghai Huilun Pharmaceutical Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin-protein ligase binding moiety coupled to an interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety through a linker reported to be useful for the treatment of cancer, neurodegeneration, infections, autoimmune disorders, metabolic diseases, cardiovascular disorders, genetic diseases and inflammatory disorders, among others.
Researchers from Zhejiang Jieyuan Med-Tech Co. Ltd. and collaborators have reported the design and preclinical characterization of a novel series of benzylamine derivatives acting as PD-1/PD-L1 inhibitors, with HD-10 being the most potent compound.
Isoniazid is a first-line medicine for tuberculosis (TB) treatment. It is a prodrug activated by the mycobacterial catalase-peroxidase enzyme KatG. However, the development of isoniazid resistance compromises treatment efficacy and contributes to multidrug-resistant TB infections.
Liver diseases are responsible for around two million deaths every year. Among them, hepatocellular carcinoma (HCC), particularly at late stages, presents limited therapeutic options and a dismal survival rate.
RSS
